The incidence of tuberculosis has been increasing substantially on a worldwide basis over
the past decade, but no tuberculosis-specific drugs have been discovered in 40 years. We …

Background The diarylquinoline TMC207 offers a new mechanism of antituberculosis action
by inhibiting mycobacterial ATP synthase. TMC207 potently inhibits drug-sensitive and drug-…

Sustaining the fight against TB Although vaccination has been successful in some countries,
tuberculosis (TB) is more prevalent in the world today than ever before, with nearly 10 …

Background Bedaquiline (Sirturo, TMC207), a diarylquinoline that inhibits mycobacterial ATP
synthase, has been associated with accelerated sputum-culture conversion in patients with …

Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment
of multi-drug resistant tuberculosis in decades. In vitro resistance to BDQ was previously …

Bedaquiline, a diarylquinoline, improved cure rates when added to a multidrug-resistant
tuberculosis (MDR-TB) treatment regimen in a previous placebo-controlled, phase 2 trial (…

On 10% oleic acid–albumin–dextrose–catalase-enriched 7H11 agar medium, the MIC at
which 90% of the isolates are inhibited for 20 strains of Mycobacterium tuberculosis was 0.5 μg …

Arising from: S. Brinster et al. Nature458, 83–86 (2009)10.1038/nature07772 ; Brinster et al.
reply Recently, Brinster et al. suggested that type II fatty-acid biosynthesis (FASII) is not a …

The objective of the present study was to identify the optimal R207910-containing regimen
to administer to patients who cannot receive rifampin (RIF) and isoniazid (INH) because of …

Background: iron is known to play a role in the susceptibility to and outcome of several
infections. In view of the increasing worldwide problem of tuberculosis, it may be important to …